Skip to main content
Have a personal or library account? Click to login
First-in-class HPLC-fluorescence method for quantification of roscovitine in plasma: Greenness assessment and application to pharmacokinetic studies in rats Cover

First-in-class HPLC-fluorescence method for quantification of roscovitine in plasma: Greenness assessment and application to pharmacokinetic studies in rats

Open Access
|Oct 2026

Abstract

This research introduces a first-in-class high-performance liquid chromatography with fluorescence detection (HPLC-FD) method for the reliable quantification of ROS in plasma. The method relies on the native fluorescence of ROS, with excitation and emission set at 280 nm and 340 nm, resp. Sample preparation involved a simple one-step protein precipitation with methanol. Chromatographic resolution of ROS and pemigatinib (PEM), which served as the internal standard (IS), was achieved using Zorbax Eclipse Plus C18 HPLC column. The mobile phase consisted of methanol and formate buffer solution. The method was validated in compliance with ICH M10 guidelines. It showed linearity across concentration range of 50–1,500 ng mL−1 (R² = 0.9991), with a lower limit of quantitation of 50 ng mL−1. Accuracy ranged from 96.8 to 103.4 %, and intra- and inter-day precision (RSD) were between 3.2 and 6.1 %. The method was successfully applied to quantify ROS in plasma samples from rats following administration of a single oral dose (25 mg kg−1), enabling the determination of key pharmacokinetic parameters, including Cmax (361.31 ng mL−1), tmax (1.75 h, t½ (2.867 h), Vd (0.077 L kg−1), CL (0.018 L h−1 kg−1), AUC (ng h mL−1) and and MRT (h). The greenness and practical applicability of the method were confirmed using four comprehensive independent metric tools. In comparison to previously reported bioanalytical approaches, the proposed method offers several practical advantages, such as reduced complexity and cost, a shorter run time, full validation, established greenness, and suitability for the clinical laboratory setting.

DOI: https://doi.org/10.2478/acph-2026-0029 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Published on: Oct 13, 2026
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2026 Ibrahim A. Darwish, Nourah Z. Alzoman, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.